Abstract
Peptide drugs generally show high performance in terms of safety, target affinity, and efficacy, but have limitations such as low bioavailability and short half-life. To improve this, new synthetic and analytical techniques have been developed, and the global market for peptide drugs has made great strides in the past few years, with novel peptide drugs being applied to multiple therapeutic areas. In line with this trend, 5 out of 55 new molecular entities (NMEs) approved by the FDA in the year 2023 were peptide drugs, which is an increasing trend in the last few years. In this review article, we will discuss the mechanisms of action and clinical indications, chemical structure and design, and pharmacokinetic perspectives of 6 FDA-approved peptide drugs in 2023 including 5 NMEs.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
